小剂量白介素-2（IL-2）可通过调控T细胞亚群平衡治疗自身免疫性疾病，但IL-2能否干预与免疫相关的糖尿病肾病尚不清楚。课题组预实验结果发现2型糖尿病肾病（T2DN）中肾脏组织IL-2表达下调， 为此提出：不同剂量，尤其是小剂量IL-2是否通过circRNA-7/IL-17A信号通路改变了T2DN中肾脏纤维化？为验证这一假说，课题组将通过db/db小鼠和原代肾小管上皮细胞模型，采用原位杂交、免疫组化、流式细胞术和circRNA-7/IL-17A siRNA干扰等手段，从动物、细胞以及分子水平等多方面探讨IL-2通过circRNA-7/IL-17A对肾小管上皮间充质转化的调控机制，明确IL-2在T2DN中发挥抗纤维化的重要作用。本研究将从小剂量IL-2治疗T2DN这个新视点为免疫稳态参与T2DN提供理论支持。

Low-dose recombined interleukin-2 (IL-2) independently ameliorate the autoimmune diseases such as lupus nephritis via regulating T cell subsets, but little is known about whether IL-2 can treat immunity-associated diabetic nephropathy. Our preliminary experimental results showed that IL-2 deficiency in type 2 diabetic nephropathy （T2DN）, the treatment effect of recombined IL-2 on T2DN still need further discussion. To this end, we hypothesized that different doses, especially low-dose recombined IL-2 altered renal fibrosis in T2DN through the circRNA-7 / IL-17A signaling pathway. In our study, type 2 diabetic nephropathy mice model - db/db mice and primary renal tubular epithelial cell model were created, in situ hybridization, immunohistochemistry, flow cytometry and circRNA-7 / IL-17A siRNA interference were uesd in multilevel, from animals, cell and molecular level, to explore the important role of recombined IL-2 on anti-fibrosis in T2DN via mesangial epithelial mesenchymal transition through circRNA-7 / IL-17A signaling pathway. These foundings will provide a novel therapeutic strategy for low-dose recombined IL-2 in the treatment of T2DN, and offer the evidence for the immune homeostasis in T2DN.